Metastatic Breast Cancer
Conditions
Keywords
TRC105, Breast Cancer, CD105, Endoglin, TRACON Pharma, Roswell Park Cancer Institute, Department of Defense
Brief summary
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer.
Detailed description
All patients were required to sign a consent form prior to undertaking any study-related procedures. Prospective patients were screened to determine if they qualified for the study within 28 days of enrollment. Patients who qualified received TRC105 i.v. over 1 to 4 hours on Day 1, Day 4, Day 8 and Day 15 of the initial 21-day cycle and Day 1, Day 8 and Day 15 of every subsequent 21-day cycle in combination with 1000 mg/m2 capecitabine BID for 14 days of each 21-day cycle. Those who tolerated TRC105 without any infusion reactions were eligible for reduced infusion durations. After 3 cycles of treatment, patients who demonstrated a response of complete response (CR), partial response (PR) or stable disease (SD) were eligible for additional treatment for up to six months (9 total cycles). Upon discussion with TRACON, patients judged by the Principal Investigator to be benefiting from treatment were able to continue treatment on this protocol beyond six months. Toxicities were graded according to the NCI CTCAE Version 4.0. Patients who exited the study for reasons other than drug-related toxicity prior to completion of the first 21-day cycle were replaced. Intra-patient dose escalation was not allowed.
Interventions
DRUGTRC105
IV
DRUGCapecitabine
oral
Sponsors
Roswell Park Cancer Institute
United States Department of Defense
Tracon Pharmaceuticals Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only) * Histologically proven metastatic Her-2-negative breast cancer (Part 2 only) * Measurable disease by RECIST 1.1 criteria (Part 2 only) * Willing and able to consent for self to participate in study * Progressive or recurrent disease after prior systemic chemotherapy regimen * Age ≥ 18 years * ECOG performance status of 0 or 1 * Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or baseline (except alopecia) * Adequate organ function
Exclusion criteria
* Prior treatment with more than one systemic chemotherapy regimen for metastatic disease. * Prior treatment with TRC105 * History of hypersensitivity reaction to antimetabolite therapy * Receipt of an investigational agent within 28 days of starting study treatment * Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment * Minor surgical procedures within 14 days prior to first dose of TRC105 * History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease * Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months * Uncontrolled chronic hypertension defined as systolic \> 140 or diastolic \> 90 despite optimal therapy * Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia * Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105 * Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month * Hemorrhage within 28 days of starting study treatment * Unhealed wounds within 28 days of starting study treatment * History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness * Known active viral or nonviral hepatitis * History of hypersensitivity reaction to human or mouse antibody products * Lung cancer with central chest lesions * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine | 1.5 years | Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D | Cycle 2 day 1 (3 weeks) | Mean trough concentration for patients dosed at 10 mg/kg at cycle 2 day 1 |
| Number of Patients With Positive Immune Response to TRC105 | 1.5 years | Serial blood samples will be tested for anti-drug antibody (ADA) immune response to TRC105. Patients who are positive at baseline (prior to receiving TRC105) are excluded from analysis. |
| Number of Patients With Objective Response According to RECIST 1.1 | 1.5 years | The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Single All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID) | 19 |
| Total | 19 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| 7.5 mg/kg TRC105, 1000 mg/m2 Cape | Adverse Event | 1 |
Baseline characteristics
| Characteristic | Single |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants |
| Age, Continuous | 53 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 15 Participants |
| Region of Enrollment United States | 19 participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 19 |
| other Total, other adverse events | 19 / 19 |
| serious Total, serious adverse events | 6 / 19 |
Outcome results
Primary
Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine
Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.
Time frame: 1.5 years
Population: All patients who received at least a portion of a dose of TRC105 enrolled in the dose escalation portion of the study
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Carotuximab (TRC105) Plus Capecitabine | Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine | Patients with DLT at 7.5 mg/kg | 0 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine | Patients without DLT at 7.5 mg/kg | 3 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine | Patients with DLT at 10 mg/kg | 0 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine | Patients without DLT at 10 mg/kg | 3 Participants |
Secondary
Number of Patients With Objective Response According to RECIST 1.1
The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type
Time frame: 1.5 years
Population: Patients who had measurable disease at baseline and received at least one follow up scan were evaluable for the primary efficacy outcome of ORR by RECIST 1.1
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Carotuximab (TRC105) Plus Capecitabine | Number of Patients With Objective Response According to RECIST 1.1 | Partial Response | 1 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Number of Patients With Objective Response According to RECIST 1.1 | Stable Disease | 3 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Number of Patients With Objective Response According to RECIST 1.1 | Progressive Disease | 12 Participants |
Secondary
Number of Patients With Positive Immune Response to TRC105
Serial blood samples will be tested for anti-drug antibody (ADA) immune response to TRC105. Patients who are positive at baseline (prior to receiving TRC105) are excluded from analysis.
Time frame: 1.5 years
Population: All patients who received at least a portion of a dose of TRC105
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Carotuximab (TRC105) Plus Capecitabine | Number of Patients With Positive Immune Response to TRC105 | Post-Dose Positive Anti-Drug Antibody | 3 Participants |
| Carotuximab (TRC105) Plus Capecitabine | Number of Patients With Positive Immune Response to TRC105 | Post-Dose Negative Anti-Drug Antibody | 16 Participants |
Secondary
TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D
Mean trough concentration for patients dosed at 10 mg/kg at cycle 2 day 1
Time frame: Cycle 2 day 1 (3 weeks)
Population: All patients who received full TRC105 doses of 10 mg/kg in cycle 1.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Carotuximab (TRC105) Plus Capecitabine | TRC105 Steady State Pharmacokinetic Trough Concentration at the RP2D | 66668.75 ng/mL |